×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RARE – ultragenyx pharmaceutical inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RARE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
10:21 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at JPMorgan Chase & Co. from $105.00 to $102.00. They now have an "overweight" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at JPMorgan Chase & Co. from $105.00 to $102.00. They now have an "overweight" rating on the stock.
11/20
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/12
11:33 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $121.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $121.00 price target on the stock.
11/9
10:30 am
rare
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
Low
Report
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
11/6
01:10 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $109.00 to $121.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Canaccord Genuity Group Inc. from $109.00 to $121.00. They now have a "buy" rating on the stock.
11/6
12:23 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
11/6
11:24 am
rare
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates [Yahoo! Finance]
Low
Report
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates [Yahoo! Finance]
11/6
09:30 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $116.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2024
04:01 pm
RARE
ultragenyx pharmaceutical inc.
BEAT
Report
-0.6%
ultragenyx pharmaceutical inc.
8/1/2024
04:05 pm
RARE
ultragenyx pharmaceutical inc.
BEAT
Report
14.3%
ultragenyx pharmaceutical inc.
5/2/2024
04:00 pm
RARE
ultragenyx pharmaceutical inc.
MISS
Report
-0.9%
ultragenyx pharmaceutical inc.
2/15/2024
04:01 pm
RARE
ultragenyx pharmaceutical inc.
BEAT
Report
5.8%
ultragenyx pharmaceutical inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
06:43 am
rare
Form SC 13G/A Ultragenyx Pharmaceutica Filed by: RTW INVESTMENTS, LP
Medium
Report
Form SC 13G/A Ultragenyx Pharmaceutica Filed by: RTW INVESTMENTS, LP
11/12
09:20 am
rare
Form 8-K Ultragenyx Pharmaceutica For: Nov 09
Medium
Report
Form 8-K Ultragenyx Pharmaceutica For: Nov 09
11/6
06:01 am
rare
Form 10-Q Ultragenyx Pharmaceutica For: Sep 30
Medium
Report
Form 10-Q Ultragenyx Pharmaceutica For: Sep 30
11/5
04:07 pm
rare
Form 8-K Ultragenyx Pharmaceutica For: Nov 05
Medium
Report
Form 8-K Ultragenyx Pharmaceutica For: Nov 05
10/11
04:49 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Oct 10 Filed by: Horn Howard
Low
Report
Form 4 Ultragenyx Pharmaceutica For: Oct 10 Filed by: Horn Howard
10/7
08:15 am
rare
Form 8-K Ultragenyx Pharmaceutica For: Oct 07
Low
Report
Form 8-K Ultragenyx Pharmaceutica For: Oct 07
10/3
04:34 pm
rare
Form 8-K Ultragenyx Pharmaceutica For: Oct 03
Low
Report
Form 8-K Ultragenyx Pharmaceutica For: Oct 03
9/18
01:03 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Sep 16 Filed by: Huizenga Theodore Alan
Low
Report
Form 4 Ultragenyx Pharmaceutica For: Sep 16 Filed by: Huizenga Theodore Alan
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/9
Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
23.4%
3/13 Form 4 Ultragenyx Pharmaceutica For: Mar 12 Filed by: KAKKIS EMIL D 10.2%
1/13 Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) 8.1%
3/9 Ultragenyx to Present at Barclays Global Healthcare Conference 7.7%
4/2 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $75.00 price target on the stock. 6.6%
6/17 Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer 6.5%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder 5.7%
7/17 Form 4 Ultragenyx Pharmaceutica For: Jul 16 Filed by: Pinion John Richard 5.1%
9/11 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.4%
4/17 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.2%
3/13 Form 4 Ultragenyx Pharmaceutica For: Mar 12 Filed by: KAKKIS EMIL D 10.2%
1/13 Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) 8.1%
3/9 Ultragenyx to Present at Barclays Global Healthcare Conference 7.7%
4/2 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $75.00 price target on the stock. 6.6%
6/17 Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer 6.5%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder 5.7%
7/17 Form 4 Ultragenyx Pharmaceutica For: Jul 16 Filed by: Pinion John Richard 5.1%
9/11 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.4%
4/17 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.2%
TOP News Decliners
3/16
GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
-21.2%
9/4 Form 8-K Ultragenyx Pharmaceutica For: Sep 04 -13.3%
3/6 Form 8-K Ultragenyx Pharmaceutica For: Mar 03 -9.3%
8/1 Form 8-K Ultragenyx Pharmaceutica For: Aug 01 -9.0%
5/7 Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 -7.0%
8/27 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.9%
3/6 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.8%
10/29 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.1%
11/5 Q3/2019 9/30/2019 EPS -1.960 ZacksConsensus -1.710 ActVsEst (0.250) - Miss -5.9%
9/3 GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 -5.8%
9/4 Form 8-K Ultragenyx Pharmaceutica For: Sep 04 -13.3%
3/6 Form 8-K Ultragenyx Pharmaceutica For: Mar 03 -9.3%
8/1 Form 8-K Ultragenyx Pharmaceutica For: Aug 01 -9.0%
5/7 Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 -7.0%
8/27 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.9%
3/6 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.8%
10/29 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.1%
11/5 Q3/2019 9/30/2019 EPS -1.960 ZacksConsensus -1.710 ActVsEst (0.250) - Miss -5.9%
9/3 GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: